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REPORT OF RISING POWERS POLICY WORKSHOP: 
GLOBAL GOVERNANCE OF HUMAN EMBRYONIC STEM CELL RESEARCH AND THERAPY – AN EXAMPLE 
FROM INDIA 
 
Held on 15 Mar 2013 at King’s College London 
 
This report has been compiled by Alex Faulkner and Saheli Datta 
and approved by the workshop participants 
 
A policy workshop was held on 15 March 2013 at King’s College London as part of the ESRC funded 
research  ‘State strategies of governance in biomedical innovation: the impact of China and India’. This 
project explores emerging innovation dynamics and trans-national governance in the context of the 
increasing importance of the life sciences and technologies in countries’ and regions’ competitive and 
collaborative economic strategies, and the recognition that biomedical sciences raise difficult questions 
of ethics and of social impact. The project involves a series of workshops, whose results are designed to 
inform public policy-making in a range of fields in regenerative and personalised medicine in the UK and 
the ‘Rising Powers’ of India and China.  
 
The objective of the workshop was to better understand the regulatory, medical, commercial and legal 
community’s perception of innovative biomedical practices in the emerging nations, and to identify the 
most relevant debates in the field of human embryonic stem cell (hESC) therapy in the context of a 
dynamic global marketplace, uncertain science and variable regulation globally.  The workshop was 
chaired by the research Principal Investigator Brian Salter, Professor of Politics in the Department of 
Political Economy, KCL, supported by Co-Investigators Dr Alex Faulkner (University of Sussex) and Dr 
Stuart Hogarth (KCL). The workshop generated wide interest and was attended by 20 delegates ranging 
from clinicians, academics, researchers, lawyers and regulators to the social sciences including sociology 
and anthropology. Professor Pranav Desai, chairperson of the Centre for Studies of Science Policy (CSSP) 
of the Jawaharlal Nehru University (JNU) in Delhi, India, a collaborating partner in the research,  
provided an introduction on the Indian context of biotech biomedical innovation in general and stem 
cell innovation in particular. 
 
Dr Geeta Shroff, a professional gynaecologist and embryologist, and founder and practitioner of 
embryonic stem cell therapy clinics in Delhi, India, presented her work in India. Dr Shroff is known 
widely as a controversial practitioner, involved in providing treatment to numbers of ‘stem cell tourists’ 
with unmet medical needs from both India and elsewhere in the world.  This report concentrates on the 
discussion prompted by Dr Shroff’s presentation.  
 
The discussions centred on the global market, the scientific community, the national Indian context, and 
ethical and regulatory dimensions of stem cell research and therapy.  Based on these central issues, this 
report presents first the ethical perceptions of UK-based participants and Dr Shroff’s position, and then 
summarises discussion about difference and commonalities of formal regulation, and issues of what sort 
of innovation model is represented by Dr Shroff’s work to date, in the context of issues of its visibility in 
scientific and wider public communities.  Finally we conclude that the workshop helped identify the 
current central areas of resistance to human embryonic stem cell therapies in ‘western’-centric scientific 
and policy perception, while emphasizing some of the local and national Indian positions and responses 
to these perceptions. The workshop helps provide pointers for future research and policy development 






The workshop discussions centred on some key concerns in stem cell therapy as practised in the 
transitioning economies: 
 
Donor consent for stem cell therapy in India – the attendees expressed concern for the nature and 
scope of consent of the in-vitro embryo donor from whom Dr Shroff’s embryonic stem cell lines are 
generated. For instance one question was to what extent consent was sought and received from the 
donor of the embryo from which Dr Shroff’s stem cell lines were generated. Dr Shroff’s response that 
she had sought consent from the donor 11 years ago and had since maintained ‘long term’ documentary 
evidence of this consent’ thus fulfilling the basic criteria as set by the Government of India for 
developing cell lines, was perceived as too simplistic and tinged with perceptions of local medical 
standards as ‘uncaring’ of donors or their consent. This view can be seen as reflecting broader public 
criticisms of the ethics of using readily available human subjects for clinical experimentation in the 
developing world. However, this negative perception vied with a pervading sense of the diffuse and 
unexplored ethical boundaries accompanying novel medical practices like stem cell therapy: “indeed it 
was impossible to have sought full consent at the time,” emphasizing the regional differences in 
attitudes to informed consent and its evolving nature. Dr Shroff obtained consent in the year 2000 when 
it was impossible for the donors, doctors or the regulatory authorities to foresee the possible global use 
of the stem cell lines.  A noteworthy basis of divergent regional ethical perceptions was perceived as 
rooted in the divergent regional religious beliefs with Catholic values surrounding abortions (and 
terminated embryos) in the Christian world being juxtaposed to Hindu beliefs in chimeras and embryos 
as fountainheads of civilizations.  
 
Human trials of embryonic stem cell therapy are still rare. Nevertheless, alleged lack of clinical trials for 
hESC in India revealed American-European scientific concerns about liberal standards of ensuring 
patient health and safety in regulatory contexts such as India’s. For instance, questions like ‘how safe is 
it to use stem cell therapy without a set number of clinical trials?’ or questions of dosage i.e. ‘how to 
determine optimum level of cell growth without trials?’ etc., revealed strong beliefs that patient health 
and safety was seen as not a sufficient priority in India. In response, Dr Shroff while agreeing to the 
necessity of clinical trials, emphazised the crucial need for alternative policies to the current norm of 
clinical trials in emerging fields such as stem cell therapy, which did not fit the standard model of 
medical treatment. For Dr Shroff, the question of RCTs before treating patients, a majority of whom are 
medically deemed as ‘terminal’ or ‘incurable,’ is a “non-sequitur” not only in terms of patient health but 
also ethically in terms of a doctor’s responsibility to use whatever means possible to cure her patients. 
In this regard, Dr Shroff’s position that “we do not harm our patients” when asked if her attitude to 
clinical trials was “typical of the Indian medical profession”, was countered by Dr Shroff’s view that such 
an attitude would be shared by any medical practitioner. So Dr Shroff’s response revealed a higher 
ethical priority accorded to “saving lives” now, rather than spending precious time running clinical trials. 
These positions were not clearcut, however, one scientist commenting that “western snobbery about 
clinical trials…that mapping the brain of a fruit fly is necessary before treating a Parkinson’s patient,” 
speaks of some divisions amongst the western scientific medical community about the appropriateness 
and proper extent of clinical trials, and the possibility of creating different trial  and evidence rules for 
promising emerging therapies.  
 
Market, Scientific Community, and Regulatory Aspects 
A set of contentious issues emerged around what might be termed some ‘closed’ or relatively invisible 
aspects of Dr Shroff’s practice in particular and more generally of the context of the prevailing standards 
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and regulation in India, when judged by those of broadly shared scientific conventions of the US, 
Western Europe and elsewhere. The central issues in these respects perceived to be of concern by many 
of the workshop attendees were: 
 
Perceived liberal regulatory oversight– revealed concerns about the lack of stringent policies for 
monitoring patient health and safety primarily grounded on perceptions of comparatively lenient 
policies being used as a tool for growing the medical enterprises of the developing world (through 
medical tourism, patenting and so on).  A view to be found in some mass media commentary on clinics 
advertising on the internet globally and expressed somewhat in the workshop, was one that many 
centres offering stem cell therapy are motivated by aims that are overarchingly economic, novel medical 
practices being seen as little more than business ventures and not centres of altruistic patient care. 
However, Dr Shroff stated that her service is not advertised (though it does have an online presence). A 
social science academic suggested that Dr Shroff’s practice, in terms of types of biomedical innovation, 
was not in fact a commercial product-based model. Raised by the subject of Dr Shroff’s application for 
worldwide patents (with both United States and European Patent offices) of her stem cell “product”, a 
critical economic perspective suggested an apparent “appetite for commercialization both within India 
and outside” in  stem cell therapy, and a regulatory view was that the “broader point is recognizing the 
policy approach- that the patent is not as crucial as regulatory protection” - such as might be granted 
through the type of market exclusivity that a regulator such as the European Medicines Agency might 
provide.  In this connection it was ‘hard to envisage’ a generic hESC product (that is, such as Dr Shroff’s) 
receiving such market protection.  
 
Further, there was detailed discussion prompted by Dr Shroff’s presentation, about the type of 
regulatory regime, the safety of hESC procedures and the evidence for safety in the context of 
regulatory control. The unclear status of hESC therapy in Indian regulation was pointed out, with 
speculation as to whether for example it should be subject to drug price controls or not – hESC could 
also be treated as transplantation, involving a different set of regulations. Dr Shroff explained how her 
stem cell lines and her clinical practice met Indian and international standards, referring to the technical 
standards of Good Manufacturing Practice, Good Clinical Practice and Good Laboratory Practice, and her 
practice having government approval. She also presented imaging data on several individual patients 
(see slides). However, these were felt to fall short of a full ‘safety profile’ and methodological rigour that 
would be expected to include timeframes, endpoints and other criteria. For instance, there was 
expressed concern about the reliability of the scientific technique used for reaching a desired ‘optimum’ 
number of cell growth in patients without the data from an acceptable number of randomised clinical 
trials (RCTs).  A regulator commented : “The use of medicinal products derived from human embryonic 
stem cells requires adequate testing of the cells at various stages of the manufacturing process with 
regard to determining the safety of the product. This is true of all medicinal products but is especially 
important in products of this type (derived from human embryonic stem cells) because of the risk of 
safety concerns developing at a late stage after administration.” Dr Shroff expressed herself as 
‘passionate about rigour’ and safety being a major concern in every step of the development of her 
techniques, which had passed government scrutiny. In relation to matters such as cell viability, 
chromosomal stability, infection-checking and cell robustness, Dr Shroff had collected data, and pointed 
out also that her cell lines were cultured (unusually) without any animal products. However, there 
apparently remained amongst workshop participants some lack of clarity about the extent to which Dr 
Shroff’s work had produced such data, and this was linked partly to the issue of publication and peer 




In line with scientific research standards, the attendees were generally agreed in considering peer-
reviewed publications, public availability of clinical and patient data, and documentation of regulatory 
approvals in the public domain as key steps in proving competence of any scientific endeavour. Dr 
Shroff’s apparent reticence and low profile to date in these matters arguably have not only shrouded 
her work in mystery but have also encouraged perceptions of her work as ill-regulated and commercially 
driven.  
 
It was generally perceived that publishing work substantiated with empirical evidence would earn Dr 
Shroff’s practice needed credibility and ‘respect.’ Dr Shroff pointed out that she had publications in the 
planning stage but was waiting until her patent applications were decided before exposing her data 
more widely to scientific and public scrutiny. She pointed out that the data in her patent applications are 
publicly available.1 It was also notable that Dr Shroff expressed an ‘open doors’ policy for interested 
parties to visit her laboratories and clinics to ‘see for themselves’, and referred to a Clinical Research 
Organisation (CRO) and clinicians who had visited the centre and given ‘positive reports’. Questioned 
about the actual sharing of cells with other scientists and practitioners in India, Dr Shroff was open to 
this, though has not made this step yet pending the patent application decision. There was some 
agreement that the type of evidence required for hESC was not the same as for conventional 
pharmaceutical clinical trials, but the need for ‘public evidence’ remained. Dr Shroff noted that her 
attempts some years ago to speak at meetings of the International Society of Stem Cell Research 
(ISSCR), a leading international scientific standards organisation, had not resulted in the offer of an 
opportunity to do so. This resulted in a suggestion that the ISSCR as an organisation had possibly 
become somewhat more representative of the stem cell science emerging from Rising Powers countries 
more recently. However, there remained a doubt expressed that Dr Shroff’s evidence base would meet 
the expectations of transnational organisations such as the ISSCR, which has a clear worry about the 
ethics of profiting from ‘vulnerable patients’, and is  currently dominated by members from the most 
powerful nationals in the life sciences including USA, UK,  other EU countries and other powerful OECD 
nations.     
 
In summary, the workshop helped identify some of the general, central areas of the developed 
economies and health systems’ resistance to human embryonic stem cell therapies allowed under a 
permissive regulatory system such as India’s, while emphasizing some of the alternative responses to 
these perceptions, and providing insight into key features of India’s alternative regulatory and political 
culture. The debates and outcomes of the workshop are expected to provide useful pointers for future 
research and policy development to understand the ‘global biopolitics’ of this innovative, developing 
field. 
 
                                                 
1http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2007141657&recNum=21&maxRec=
21&office=&prevFilter=&sortOption=Pub+Date+Desc&queryString=FP%3A%28geeta+shroff%
29&tab=PCTDescription 
 
